Celanese and Secarna Pharmaceuticals Announce Collaboration on Antisense Therapy Development

Celanese Corporation and Secarna Pharmaceuticals GmbH & Co. KG have announced a new research collaboration focused on the development of long-acting implants for the delivery of antisense oligonucleotides (ASOs), aiming to improve treatment for a variety of diseases. This partnership seeks to utilize Celanese's VitalDose® Drug Delivery Platform alongside Secarna’s proprietary ASO Drug Discovery and Development Platform to create implants capable of reducing dosing frequency, minimizing off-target effects, and enhancing patient outcomes. The collaboration underscores both companies' commitment to advancing patient-centric solutions in the antisense therapy space.

Antisense therapies, which target specific messenger RNA to block the production of disease-related proteins, have shown promise across a range of conditions, including cardiometabolic, central nervous system, oncological, and rare diseases. However, the need for frequent administration or high doses has posed a challenge. The joint effort by Celanese and Secarna aims to address these issues by developing a delivery system that ensures controlled, long-term release of therapeutic agents, thus potentially transforming the administration of ASO therapies.

Celanese's expertise in material sciences and drug delivery systems combines with Secarna’s capabilities in drug discovery and development to pave the way for innovative treatments. The collaboration highlights a strategic approach to leverage complementary technologies for the advancement of therapeutic options, offering hope for enhanced treatment strategies for patients with serious health conditions.